36 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Carcinoid Tumor" (36 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
2 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
3 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
4 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
5 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
6 Recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
7 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
8 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
9 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
10 Recruiting YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
Condition: Carcinoid
Intervention: Drug: YF476
11 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
12 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
13 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
14 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
15 Available [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
16 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
17 Recruiting Theranostics: 68GaDOTATOC and 90YDOTATOC
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Interventions: Drug: 90Y-DOTA-tyr3-Octreotide;   Radiation: Dosimetry-Guided Peptide Receptor Radiotherapy;   Drug: Aminosyn II
18 Not yet recruiting Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Intervention: Drug: 68Ga-DOTATOC PET/CT
19 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
20 Recruiting Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Conditions: Neuroendocrine Tumor;   Paraganglioma;   Carcinoid Tumors;   Neuroblastoma
Intervention: Drug: DOTA-TOC PET/CT

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years